|
|
|
 |
|
 |
 |
|||
Company News
|
SONITUS MEDICAL CLOSES $25 MILLION
SERIES D ROUND OF VENTURE CAPITAL FINANCING
New Investor Abingworth Leads Round; Takes Board Seat
San Mateo, California, 15 May 2012
- Sonitus Medical, Inc., a medical device company that manufactures the world's first non-surgical and removable hearing device to transmit sound via the teeth, today announced that it has closed a $25 million Series D round of venture capital funding. Abingworth, an international investor dedicated to life sciences, led the round and was joined by all current venture capital investors.
top
Cytos Biotechnology Ltd Completes the CHF 23.75 Million equity portion of its planned CHF 37 Million Financing
New financing will allow further development of CYT003, a novel treatment for asthma
Large global Phase IIb program with CYT003 in asthma planned to start in 2H12
New Directors with significant life science experience join the Cytos Board
Switzerland, 15 May 2012
top
Sientra Raises $65 Million in a Series C Financing to Support Commercialization of its FDA-Approved Silicone Breast Implants.
Santa Barbara, California, USA, 28 March 2012
top
Cytos to raise up to CHF 37 million from international and strategic investors to advance asthma clinical program.
Novel Immunodrug™ candidate CYT003 offers exciting new approach to asthma therapy
Switzerland, 21 March 2012
top
Amgen to Acquire Micromet
Acquisition Includes a Novel Cancer Treatment in Clinical Trials for Hematologic Malignancies
Micromet's Proprietary BiTE® Platform has Potential to Improve Treatment in Multiple Tumor Types All-Cash Transaction Values Micromet at $1.16 Billion
California, USA, 30 January 2012
top
CELGENE TO ACQUIRE AVILA THERAPEUTICS
Oral Btk inhibitor AVL-292 offers promising potential for treatment of B-cell diseases. Avilomics™ Platform enhances drug discovery capabilities
Summit, NJ and Bedford, MA, 26 January 2012
top
Prosensa Raises €23 Million in New Equity Financing Led by New Enterprise Associates
Leiden, The Netherlands, 25 January 2012
top
SFJ PHARMA LTD. II, ANNOUNCES AGREEMENT WITH PFIZER TO DEVELOP AXITINIB FOR ADJUVANT TREATMENT OF RENAL CELL CARCINOMA
San Francisco, 09 January 2012
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||
